Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 16 of 65 · 3100 articles
Colon-targeted prednisolone devices could lower upper-GI exposure to steroids and provide sustained local therapy, which may be relevant for IBD treatment strategies if later validated in vivo and in clinical trials.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
The case links thymic hyperplasia, thyroid autoimmunity, and severe UC with colorectal neoplasia, suggesting possible shared immune dysregulation that might interest patients and clinicians, but it does not support...
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...
m6A RNA methylation is a regulator of RNA function that may influence inflammation, immunity, and the intestinal microbiota — all central to IBD. Understanding these pathways could identify new biomarkers or drug targets...
Patients with IBD who may need dupilumab for another immune condition could benefit from evidence about whether combining dupilumab with IBD biologics or advanced therapies changes infection or healthcare-utilization...
Finding genetic variants that correlate with country-level IBD burden could help researchers study why IBD rates differ geographically and point to biological pathways relevant to disease risk and outcomes.
This study describes a novel, non‑drug HA‑based nano‑assembly that targets inflammatory M1 macrophages and reshapes the colonic immune environment in mouse models of ulcerative colitis — a potential new therapeutic...
New Phase II trials test whether a gut-activated oral PDE4 inhibitor can treat moderate-to-severe ulcerative colitis and Crohn’s while avoiding systemic PDE4 tolerability issues; positive Phase II results could add a new...
This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...
This project targets epithelial repair — a mechanism not directly addressed by most current IBD drugs — and reports early human safety/tolerability data, so it could lead to a new oral therapy for inducing and...
Researchers are studying how gut bacteria evade therapeutic phages, which could affect development of phage-based treatments for drug-resistant infections and potentially influence understanding of bacteria linked to IBD...
Malnutrition and impaired growth are common at diagnosis in paediatric IBD—especially Crohn’s disease—and identifying these issues early can guide nutrition and treatment planning. Most underweight children in this study...
This study maps a shared transcriptional programme linking inflamed IBD tissue to colorectal cancer pathways, highlighting potential biomarker and prevention targets relevant to the inflammation-to-cancer transition.
Fecal calprotectin is commonly used to monitor IBD activity. If bowel prep raises calprotectin modestly, that could affect how post-procedure results are interpreted and avoid unnecessary treatment changes.
Tools that predict which microbial or tumor peptides engage patient T cells could help researchers find antigens that trigger or drive autoimmune conditions (like some IBD cases) or that serve as targets for...
This study describes an engineered probiotic that senses a validated IBD inflammation biomarker (calprotectin) and produces IL‑2 locally, offering a potential new way to deliver anti‑inflammatory therapy on demand.
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...
Consistent, accurate endoscopic scoring matters for treatment decisions and trial outcomes in pediatric IBD. If focused training meaningfully improves scoring—especially for SES‑CD—it could reduce variability in clinical...
If confirmed, genetic evidence that higher omega-3 levels or a lower omega-6/omega-3 ratio relate to lower Crohn’s disease risk could point to biological pathways worth studying and might guide research into prevention...
People with Sjögren syndrome or clinicians caring for them may be interested because genetic data suggest Sjögren syndrome could modestly raise gastric ulcer risk and — unexpectedly — associate with lower IBS risk, while...
IBD patients have higher risk of colitis-associated colorectal cancer; this study suggests dietary choline might protect the intestinal barrier and reduce inflammation-driven tumor risk via a nutrient–transporter–Notch1...
People with IBD in remission commonly continue to have IBS-like symptoms; this review summarizes randomized trial evidence for symptom-directed treatments and finds no definitive best option.
Researchers are exploring ways to durably modulate macrophages in ulcerative colitis because persistent pro-inflammatory macrophages sustain tissue inflammation and impair healing.
Researchers are exploring natural compounds that might modulate immune pathways implicated in IBD. This study highlights ergothioneine as a bioactive mushroom compound that reduces pro-inflammatory signals in immune...
People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...
If confirmed, starting effective biologic therapy at diagnosis could lower the chance of surgery and complications over several years for people with moderate-to-severe Crohn’s disease.
The release reports many active and planned clinical trials for Crohn’s disease that could lead to new treatment options in coming years. It names specific late-stage and combination studies relevant to patients with...
Reported IBD rates in Brazil increased markedly between 2012 and 2025, which could mean more people will need diagnosis, specialist care, and medications. Rising numbers also matter for public-health planning and...
This study compares first‑line vedolizumab versus TNF antagonist strategies in biologic‑naive ulcerative colitis patients over multiple years — information that could affect treatment choice and expectations about...
Finding reliable diagnostic biomarkers could help detect UC earlier and clarify immune mechanisms that drive disease; GPR97 is proposed here as such a marker and a possible immunomodulatory target, which may interest...
Spatial mapping of immune niches in refractory UC identified tissue signatures (neutrophil-rich ulcer-bed niches and TLS/plasma-cell programmes) that were associated with failure to respond to biologic drugs across adult...
This review reframes IBD as a systemic disease influenced by gut microbes, metabolism, and immune interactions — which matters because it points toward better ways to stratify patients, monitor disease, and personalize...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Drug Delivery and...
This trial tests several targeted therapies (including risankizumab) alone and in combination for adults with moderate to severe Crohn's disease, aiming to measure endoscopic remission and safety. Positive findings could...
This study suggests a specific four-strain probiotic cocktail may better protect against experimental colitis than the three-strain mix, potentially via microbiota-driven increases in spermidine — a microbial metabolite...
Distinguishing colorectal cancer from IBD-related inflammatory thickening can be challenging but crucial for treatment decisions. If validated, DECT parameters could offer a noninvasive tool to improve diagnostic...
People with IBD may be interested because the review highlights a class of dietary polyphenols that could influence inflammation and immune pathways involved in Crohn’s disease and ulcerative colitis. It summarizes...
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Nature Genetics.
This study identifies a fibroblast-ILC3-pDC pathway that may help restrain gut inflammation and appears reduced in IBD tissue, highlighting a new non-immune cell mechanism relevant to disease biology.
The paper identifies a neutrophil-related immune pathway (KARAP → IDO1–kynurenine → AhR → IL-22) that contributes to mucosal inflammation in ulcerative colitis, suggesting a potential new target for research and drug...
People with ulcerative colitis may be interested in plant-based therapies that could reduce gut inflammation or support mucosal health. This review compiles preclinical evidence suggesting Terminalia arjuna has...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Inflammation Research.
This review highlights a plant-derived compound, ferulic acid, that showed anti-colitis effects in experimental studies, suggesting a potential new adjunctive therapy pathway worth watching for future clinical research.
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.
This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase...
